Yesterday, biotech Abliva, whose focus is on primary mitochondrial diseases, announced that it has decided on a 200 million SEK financing round. The funding consists of a directed share issue of approximately 150 million SEK and a rights issue of approximately 50 million SEK. Abliva’s CEO Ellen Donnelly told BioStock about raising capital under challenging market conditions and how the proceeds will be used.
See the interview with Abliva’s CEO Ellen Donnelly, in English, below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.